Literature DB >> 10210705

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.

E Kenny-Walsh1.   

Abstract

BACKGROUND AND METHODS: In February 1994, batches of anti-D immune globulin used in Ireland during 1977 and 1978 to prevent Rh isoimmunization were found to be contaminated with hepatitis C virus (HCV) from a single infected donor. In March 1994, a national screening program was initiated for all women who had received anti-D immune globulin between 1970 and 1994. Of the 62,667 women who had been screened when this study began, 704 (1.1 percent) had evidence of past or current HCV infection, and 390 of those 704 (55 percent) had positive tests for serum HCV RNA on reverse-transcription-polymerase-chain-reaction analysis. All 390 were offered a referral for clinical assessment and therapy. We evaluated 376 of these 390 women (96 percent); the other 14 were not seen at one of the designated treatment centers.
RESULTS: The mean (+/-SD) age of the 376 women was 45+/-6 years at the time of screening. They had been infected with hepatitis C for about 17 years. A total of 304 women (81 percent) reported symptoms, most commonly fatigue (248 [66 percent]). Serum alanine aminotransferase concentrations were slightly elevated (40 to 99 U per liter) in 176 of 371 women (47 percent), and the concentrations were 100 U per liter or higher in 31 (8 percent). Liver biopsies showed inflammation in 356 of 363 women (98 percent); in most cases the inflammation was slight (41 percent) or moderate (52 percent). Although the biopsy samples from 186 of the 363 women (51 percent) showed evidence of fibrosis, only 7 women (2 percent) had probable or definite cirrhosis. Two of the seven reported excessive alcohol consumption.
CONCLUSIONS: Most of the women with HCV infection 17 years after receiving HCV-contaminated anti-D immune globulin had evidence of slight or moderate hepatic inflammation on liver biopsy, about half had fibrosis, and 2 percent had probable or definite cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10210705     DOI: 10.1056/NEJM199904223401602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  192 in total

1.  Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C.

Authors:  L Kleinman; M W Zodet; Z Hakim; J Aledort; C Barker; K Chan; L Krupp; D Revicki
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

2.  Heavy drinking greatly increases the risk of cirrhosis in patients with HCV hepatitis.

Authors:  C P Day
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

3.  Health and socioeconomic status differences among antibody hepatitis C positive and negative transfusion recipients, 1986-1990.

Authors:  Robert S Hogg; Kevin J P Craib; David Pi; Samuel S Lee; Gerald Y Minuk; Colin M Shapiro; Martin T Schechter; Michael V O'Shaughnessy
Journal:  Can J Public Health       Date:  2003 Mar-Apr

4.  Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection.

Authors:  Chao-Hung Hung; Jing-Houng Wang; Tsung-Hui Hu; Chien-Hung Chen; Kuo-Chin Chang; Yi-Hao Yen; Yuan-Hung Kuo; Ming-Chao Tsai; Sheng-Nan Lu; Chuan-Mo Lee
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

5.  Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study.

Authors:  K A Forde; K Haynes; A B Troxel; S Trooskin; M T Osterman; S E Kimmel; J D Lewis; V Lo Re
Journal:  J Viral Hepat       Date:  2011-11-13       Impact factor: 3.728

6.  Management of chronic hepatitis C and prevention of hepatocellular carcinoma.

Authors:  Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

7.  Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

Authors:  Miguel Arguedas
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

8.  [Postexposure prevention after occupational exposure to HBV, HCV and HIV].

Authors:  U Sarrazin; R Brodt; C Sarrazin; S Zeuzem
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639

9.  Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia.

Authors:  Mark H Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chloe L Thio; Marion G Peters; Norah A Terrault; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Tiffany G Harris; Mary A Young; Howard D Strickler; Mary Carrington
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

10.  Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.

Authors:  Silvia Manfroi; Chiara Calisesi; Pietro Fagiani; Annalisa Gabriele; Gianluca Lodi; Simonetta Nucci; Susanna Pelliconi; Laura Righini; Vanda Randi
Journal:  Blood Transfus       Date:  2018-04-09       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.